Skip to main content
SpringerLink
Log in

Nabumetone

Therapeutic Use and Safety Profile in the Management of Osteoarthritis and Rheumatoid Arthritis

  • Review Article
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Nabumetone is a nonsteroidal anti-inflammatory prodrug, which exerts its pharmacological effects via the metabolite 6-methoxy-2-naphthylacetic acid (6-MNA). Nabumetone itself is non-acidic and, following absorption, it undergoes extensive first-pass metabolism to form the main circulating active metabo-lite (6-MNA) which is a much more potent inhibitor of preferentially cyclo-oxygenase (COX)-2. The three major metabolic pathways of nabumetone are O-demethylation, reduction of the ketone to an alcohol, and an oxidative cleavage of the side-chain occurs to yield acetic acid derivatives. Essentially no unchanged nabumetone and <1% of the major 6-MNA metabolite are excreted unchanged in the urine from which 80% of the dose can be recovered and another 10% in faeces.

Nabumetone is clinically used mainly for the management of patients with osteoarthritis (OA) or rheumatoid arthritis (RA) to reduce pain and inflammation. The clinical efficacy of nabumetone has also been evaluated in patients with ankylosing spondylitis, soft tissue injuries and juvenile RA.

The optimum oral dosage of nabumetone for OA patients is 1g once daily, which is well tolerated. The therapeutic response is superior to placebo and similar to nonselective COX inhibitors. In RA patients, nabumetone 1g at bedtime is optimal, but an additional 0.5–1 g can be administered in the morning for patients with persistent symptoms. In RA, nabumetone has shown a comparable clinical efficacy to aspirin (acetylsalicylic acid), diclofenac, piroxicam, ibuprofen and naproxen.

Clinical trials and a decade of worldwide safety data and long-term postmarketing surveillance studies show that nabumetone is generally well tolerated. The most frequent adverse effects are those commonly seen with COX inhibitors, which include diarrhoea, dyspepsia, headache, abdominal pain and nausea.

In common with other COX inhibitors, nabumetone may increase the risk of GI perforations, ulcerations and bleedings (PUBs). However, several studies show a low incidence of PUBs, and on a par with the numbers reported from studies with COX-2 selective inhibitors and considerably lower than for nonselective COX inhibitors. This has been attributed mainly to the non-acidic chemical properties of nabumetone but also to its COX-1/COX-2 inhibitor profile. Through its metabolite 6-MNA, nabumetone has a dose-related effect on platelet aggregation, but no effect on bleeding time in clinical studies. Furthermore, several short-term studies have shown little to no effect on renal function.

Compared with COX-2 selective inhibitors, nabumetone exhibits similar anti-inflammatory and analgesic properties in patients with arthritis and there is no evidence of excess GI or other forms of complications to date.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Data on file, Meda AB (Solna, Sweden), 2004

  2. Smith CJ, Morrow JD, Roberts LJ, et al. Induction of prostaglandin endoperoxide synthase-1 (COX-1) in a human promonocytic cell line by treatment with the differentiating agent TPA. Adv Exp Med Biol 1997; 400A: 99–106

    Article  PubMed  CAS  Google Scholar 

  3. Rocca B, Spain LM, Pure E, et al. Distinct roles of prostaglandin H synthases 1 and 2 in T-cell development. J Clin Invest 1999; 103(10): 1469–77

    Article  PubMed  CAS  Google Scholar 

  4. Marnett LJ, Rowlinson SW, Goodwin DC, et al. Arachidonic acid oxygenation by COX-1 and COX-2: mechanisms of catalysis and inhibition. J Biol Chem 1999; 274(33): 22903–6

    Article  PubMed  CAS  Google Scholar 

  5. Pash JM, Bailey JM. Inhibition by corticosteroids of epidermal growth factor-induced recovery of cyclooxygenase after aspirin inactivation. FASEB J 1988; 2(10): 2613–8

    PubMed  CAS  Google Scholar 

  6. Sebaldt RJ, Sheller JR, Oates JA, et al. Inhibition of eicosanoid biosynthesis by glucocorticoids in humans. Proc Natl Acad Sci U S A 1990; 87(18): 6974–8

    Article  PubMed  CAS  Google Scholar 

  7. Masferrer JL, Zweifel BS, Seibert K, et al. Selective regulation of cellular cyclooxygenase by dexamethasone and endotoxin in mice. J Clin Invest 1990; 86(4): 1375–9

    Article  PubMed  CAS  Google Scholar 

  8. Xie WL, Chipman JG, Robertson DL, et al. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci U S A 1991; 88(7): 2692–6

    Article  PubMed  CAS  Google Scholar 

  9. Kujubu DA, Herschman HR. Dexamethasone inhibits mitogen induction of the TIS10 prostaglandin synthase/cyclooxygenase gene. J Biol Chem 1992; 267(12): 7991–4

    PubMed  CAS  Google Scholar 

  10. O’Banion MK, Winn VD, Young DA. cDNA cloning and functional activity of a glucocorticoid-regulated inflammatory cyclooxygenase. Proc Natl Acad Sci U S A 1992; 89(11): 4888–92

    Article  PubMed  Google Scholar 

  11. Lee SH, Soyoola E, Chanmugam P, et al. Selective expression of mitogen-inducible cyclooxygenase in macrophages stimulated with lipopolysaccharide. J Biol Chem 1992; 267(36): 25934–8

    PubMed  CAS  Google Scholar 

  12. Sheng H, Shao J, Dixon DA, et al. Transforming growth factor-beta1 enhances Ha-ras-induced expression of cyclooxygenase-2 in intestinal epithelial cells via stabilization of mRNA. J Biol Chem 2000; 275(9): 6628–35

    Article  PubMed  CAS  Google Scholar 

  13. Crofford LJ, Wilder RL, Ristimaki AP, et al. Cyclooxygenase-1 and -2 expression in rheumatoid synovial tissues: effects of interleukin-1 beta, phorbol ester, and corticosteroids. J Clin Invest 1994; 93(3): 1095–101

    Article  PubMed  CAS  Google Scholar 

  14. Schonbeck U, Sukhova GK, Graber P, et al. Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions. Am J Pathol 1999; 155(4): 1281–91

    Article  PubMed  CAS  Google Scholar 

  15. Loll PJ, Picot D, Garavito RM. The structural basis of aspirin activity inferred from the crystal structure of inactivated prostaglandin H2 synthase. Nat Struct Biol 1995; 2(8): 637–43

    Article  PubMed  CAS  Google Scholar 

  16. Kurumbail RG, Stevens AM, Gierse JK, et al. Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature 1996; 384(6610): 644–8

    Article  PubMed  CAS  Google Scholar 

  17. Malkowski MG, Ginell SL, Smith WL, et al. The productive conformation of arachidonic acid bound to prostaglandin synthase. Science 2000; 289(5486): 1933–7

    Article  PubMed  CAS  Google Scholar 

  18. Freeman AMUN, Thawley AR, Golding DN. Plasma and synovial fluid concentrations of nabumetone and BRL 10720 in patients given nabumetone. In: Panayi GS, Price JD, Rotman H, editors. Nabumetone: a novel anti-inflammatory. International Congress and Symposium Series (ICSS) 69. London: Royal Society of Medicine Press, 1985: 37–42

    Google Scholar 

  19. Boyle EA, Freeman PC, Mangan FR, et al. Nabumetone (BRL 14777, 4-[6-methoxy-2-naphthyl]-butan-2-one): a new antiinflammatory agent. J Pharm Pharmacol 1982; 34(9): 562–9

    Article  PubMed  CAS  Google Scholar 

  20. Hyneck ML. An overview of the clinical pharmacokinetics of nabumetone. J Rheumatol 1992; 19 Suppl. 36: 20–4

    Google Scholar 

  21. Davies NM. Clinical pharmacokinetics of nabumetone: the dawn of selective cyclo-oxygenase-2 inhibition? Clin Pharmacokinet 1997; 33(6): 404–16

    Article  PubMed  CAS  Google Scholar 

  22. Barnett J, Chow J, Ives D, et al. Purification, characterization and selective inhibition of human prostaglandin G/H synthase 1 and 2 expressed in the baculovirus system. Biochim Biophys Acta 1994; 1209(1): 130–9

    Article  PubMed  CAS  Google Scholar 

  23. Laneuville O, Breuer DK, Dewitt DL, et al. Differential inhibition of human prostaglandin endoperoxide H synthases-1 and -2 by nonsteroidal anti-inflammatory drugs. J Pharmacol Exp Ther 1994; 271(2): 927–34

    PubMed  CAS  Google Scholar 

  24. Patrignani P, Panara MR, Greco A, et al. Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases. J Pharmacol Exp Ther 1994; 271(3): 1705–12

    PubMed  CAS  Google Scholar 

  25. Schoen RT, Vender RJ. Mechanisms of nonsteroidal anti-inflammatory drug-induced gastric damage. Am J Med 1989; 86(4): 449–58

    Article  PubMed  CAS  Google Scholar 

  26. Lichtenstein DR, Syngal S, Wolfe MM. Nonsteroidal antiin-flammatory drugs and the gastrointestinal tract: the doubleedged sword. Arthritis Rheum 1995; 38(1): 5–18

    Article  PubMed  CAS  Google Scholar 

  27. Richardson CE, Emery P. Innovative treatment approaches for rheumatoid arthritis: new cyclo-oxygenase and cytokine inhibitors. Baillieres Clin Rheumatol 1995; 9(4): 731–58

    Article  PubMed  CAS  Google Scholar 

  28. Blower PR. The unique pharmacologic profile of nabumetone. J Rheumatol 1992; 19 Suppl. 36: 13–9

    Google Scholar 

  29. Brett MA, Buscher G, Ellrich E, et al. Lack of enterohepatic circulation of the active metabolite of nabumetone in humans. J Rheumatol 1992; 19 Suppl. 36: 81–2

    Google Scholar 

  30. Mangan FR, Flack JD, Jackson D. Preclinical overview of nabumetone: pharmacology, bioavailability, metabolism, and toxicology. Am J Med 1987 Oct 30; 83(4B): 6–10

    Article  PubMed  CAS  Google Scholar 

  31. Jackson RE, Mitchell FN, Brindley DA. Safety evaluation of nabumetone in United States clinical trials. Am J Med 1987; 83(4B): 115–20

    Article  PubMed  CAS  Google Scholar 

  32. Dollery C. Therapeutic drugs. 2nd ed. Edinburgh: Churchill Livingstone, 1999

    Google Scholar 

  33. Haddock RE, Jeffery DJ, Lloyd JA, et al. Metabolism of nabumetone (BRL 14777) by various species including man. Xenobiotica 1984; 14(4): 327–37

    Article  PubMed  CAS  Google Scholar 

  34. von Schrader HW, Buscher G, Dierdorf D, et al. Nabumetone: a novel anti-inflammatory drug: bioavailability after different dosage regimens. Int J Clin Pharmacol Ther Toxicol 1984; 22(12): 672–6

    Google Scholar 

  35. Bourke BU, Thawley AR. An investigation into the penetration of nabumetone and its metabolites into synovial fluid in patients with rheumatoid arthritis. In: Panayi GS, Price JD, Rotman H, editors. Nabumetone: a novel anti-inflammatory. International Congress and Symposium Series (ICSS) 69. London: Royal Society of Medicine Press, 1985: 31–5

    Google Scholar 

  36. Sweetman SC. Martindale: the complete drug reference. 33rd ed. London: Pharmaceutical Press, 2002

    Google Scholar 

  37. Haig A, Flavin S, Macdonald B, et al. An open label study to establish dosing recommendations for nabumetone in juvenile rheumatoid arthirtis. J Rheumatol 2003 Apr; 30(4): 829–31

    PubMed  Google Scholar 

  38. Ladely D, Lewitt B, Boike S. A study of the safety and pharmacokinetics of nabumetone and 6-MNA, and the protein binding of 6-MNA in patients with juvenile rheumatoid arthritis and in healthy adult volunteers following repeated oral doses of nabumetone (1000 mg) chewable tablets. SmithKline Beecham (now GlaxoSmithKline), 1997. Solna, Sweden: Meda AB, 1997 (Data on file)

    Google Scholar 

  39. Ostrov BE. Use of nabumetone (nab) to treat juvenile rheumatoid arthritis in children intolerant to other non-steroidal anti-inflammatory drugs [abstract no. 191]. Arthritis Rheum 1996; 39 (9 Suppl.): S58

    Google Scholar 

  40. Hamdy RC, Price JD, Undre NA, et al. The pharmacokinetics of nabumetone in elderly patients. In: Panayi GS, Price JD, Rotman H, editors. Nabumetone: a novel anti-inflammatory. International Congress and Symposium Series (ICSS) 69. London: Royal Society of Medicine Press, 1985: 173–83

    Google Scholar 

  41. Maleev A, Vlahov V, Gruev I, et al. Liver insufficiency as a factor modifying the pharmacokinetic characteristic of the preparation nabumetone. Int J Clin Pharmacol Ther Toxicol 1986; 24(8): 425–9

    PubMed  CAS  Google Scholar 

  42. Clarke A, Hawkins S, Henderson RC, et al. Pharmacokinetics of nabumetone (BRL 14777) and its safety at steady state in patients with moderately imparied renal function [abstract]. Proceedings of the 2nd European Congress of Biopharmaceutics and Pharmacokinetics; 1984 Apr 24–27; Salamanca

  43. Brier ME, Sloan RS, Aronoff GR. Population pharmacokinetics of the active metabolite of nabumetone in renal dysfunction. Clin Pharmacol Ther 1995; 57(6): 622–7

    Article  PubMed  CAS  Google Scholar 

  44. Hilleman DE, Mohiuddin SM, Lucas Jr BD. Nonsteroidal anti-inflammatory drug use in patients receiving warfarin: emphasis on nabumetone. Am J Med 1993; 95(2A): 30S–4S

    Article  PubMed  CAS  Google Scholar 

  45. Chan TY. Adverse interactions between warfarin and nonsteroidal antiinflammatory drugs: mechanisms, clinical significance, and avoidance. Ann Pharmacother 1995 Dec; 29(12): 1274–83

    PubMed  CAS  Google Scholar 

  46. Jennings MB, Alfieri DM, Jules KT, et al. A double-blind study of the effect on hemostasis of nabumetone (Relafen) compared to placebo. J Foot Ankle Surg 2000; 39(3): 168–73

    Article  PubMed  CAS  Google Scholar 

  47. Friedel HA, Langtry HD, Buckley MM. Nabumetone: a reappraisal of its pharmacology and therapeutic use in rheumatic diseases. Drugs 1993; 45(1): 131–56

    Article  PubMed  CAS  Google Scholar 

  48. Whelton A, White WB, Bello AE, et al. Effects of celecoxib and rofecoxib on blood pressure and edema in patients > or = 65 years of age with systemic hypertension and osteoarthritis. Am J Cardiol 2002 Nov 1; 90(9): 959–63

    Article  PubMed  CAS  Google Scholar 

  49. Dollery C. Therapeutic drugs. 2nd ed. Edinburgh: Churchill Livingstone, 1999

    Google Scholar 

  50. Bellamy N, Bensen WG, Beaulieu A, et al. A multicenter study of nabumetone and diclofenac SR in patients with osteoarthritis. J Rheumatol 1995; 22(5): 915–20

    PubMed  CAS  Google Scholar 

  51. Lister BJ, Poland M, DeLapp RE. Efficacy of nabumetone versus diclofenac, naproxen, ibuprofen, and piroxicam in osteoarthritis and rheumatoid arthritis. Am J Med 1993; 95(2A): 2S–9S

    Article  PubMed  CAS  Google Scholar 

  52. Blechman WJ. Nabumetone therapy of osteoarthritis: a six-week, placebo-controlled study. Am J Med 1987; 83(4B): 70–3

    Article  PubMed  CAS  Google Scholar 

  53. Gillgrass J, Grahame R. Nabumetone: a double-blind study in osteoarthrosis. Pharmatherapeutica 1984; 3(9): 592–4

    PubMed  CAS  Google Scholar 

  54. Pisko EJ, Strader K, Rice D, et al. A 6-month, double-blind study comparing nabumetone to naproxen in the treatment of osteoarthritis. Pharmatherapeutica 1987; 5(2): 90–8

    PubMed  CAS  Google Scholar 

  55. Appelrouth DJ, Baim S, Chang RW, et al. Comparison of the safety and efficacy of nabumetone and aspirin in the treatment of osteoarthritis in adults. Am J Med 1987; 83(4B): 78–81

    Article  PubMed  CAS  Google Scholar 

  56. Cha HS, Koh JH, Jeon CH, et al. Comparison of the efficacy and safety of naproxen CR and nabumetone in the treatment of patients with osteoarthritis of the knee. Int J Clin Pharmacol Ther 2001; 39(12): 539–45

    PubMed  CAS  Google Scholar 

  57. Fleischmann RM. Clinical efficacy and safety of nabumetone in rheumatoid arthritis and osteoarthritis. J Rheumatol 1992; 19 Suppl. 36: 32–40

    Google Scholar 

  58. Turner Jr RA, Brindley DA, Mitchell FN. Nabumetone: a single-center three-week comparison with placebo in the treatment of rheumatoid arthritis. Am J Med 1987; 83(4B): 36–9

    Article  PubMed  Google Scholar 

  59. Lanier BG, Turner Jr RA, Collins RL, et al. Evaluation of nabumetone in the treatment of active adult rheumatoid arthritis. Am J Med 1987; 83(4B): 40–3

    Article  PubMed  CAS  Google Scholar 

  60. Brobyn RD. Nabumetone in the treatment of active adult rheumatoid arthritis. Am J Med 1987; 83(4B): 50–4

    Article  PubMed  CAS  Google Scholar 

  61. Pownall R, Knapp MS, Kowanko IC, et al. The therapeutic effectiveness of nabumetone given at different times of day including domiciliary self-measurement of circadian variations in the signs and symptoms of rheumatoid arthritis. In: Panayi GS, Price JD, Rotman H, editors. Nabumetone: a novel anti-inflammatory. International Congress and Symposium Series (ICSS) 69. London: Royal Society of Medicine Press, 1985: 113–23

    Google Scholar 

  62. Krug H, Broadwell LK, Berry M, et al. Tolerability and efficacy of nabumetone and naproxen in the treatment of rheumatoid arthritis. Clin Ther 2000; 22(1): 40–52

    Article  PubMed  CAS  Google Scholar 

  63. Bernhard GC, Appelrouth DJ, Bankhurst AD, et al. Long-term treatment of rheumatoid arthritis comparing nabumetone with aspirin. Am J Med 1987; 83(4B): 44–9

    Article  PubMed  CAS  Google Scholar 

  64. Department Rheumatology, PLA General Hospital Beijing 100853 China. Comparison of the efficacy and safety of nabumetone and diclofenc sodium in the treatment of patients with rheumatoid arthritis. Zhonghua Yi Xue Za Zhi 2001; 81(9): 557–60

    Google Scholar 

  65. Wojtulewski JA. A double-blind study of nabumetone in rheumatoid arthritis. In: Panayi GS, Price JD, Rotman H, editors. Nabumetone: a novel anti-inflammatory. International Congress and Symposium Series (ICSS) 69. London: Royal Society of Medicine Press, 1985: 79–88

    Google Scholar 

  66. Zoma A, Capell H. Double-blind study to compare the effectiveness and tolerance of nabumetone with indomethacin in patients with rheumatoid arthritis attending a hospital outpatient clinic. In: Panayi GS, Price JD, Rotman H, editors. Nabumetone: a novel anti-inflammatory. International Congress and Symposium Series (ICSS) 69. London: Royal Society of Medicine Press, 1985: 73–8

    Google Scholar 

  67. Goodman S, Howard P, Haig A, et al. An open label study to establish dosing recommendations for nabumetone in juvenile rheumatoid arthritis. J Rheumatol 2003; 30(4): 829–31

    PubMed  CAS  Google Scholar 

  68. Short DJ, Brierley J, Hajiroussou V, et al. Comparison of nabumetone with indomethacin in the treatment of ankylosing spondylitis. In: Panayi GS, Price JD, Rotman H, editors. Nabumetone: a novel anti-inflammatory. International Congress and Symposium Series (ICSS) 69. London: Royal Society of Medicine Press, 1985: 125–30

    Google Scholar 

  69. Palferman TG, Webley M. A comparative study of nabumetone and indomethacin in ankylosing spondylitis. Eur J Rheumatol Inflamm 1991; 11(2): 23–9

    PubMed  CAS  Google Scholar 

  70. Crean DM, Rotman H. An interim report of a study on the effect of nabumetone versus ibuprofen in acute soft-tissue injuries in sport. In: Panayi GS, Price JD, Rotman H, editors. Nabumetone: a novel anti-inflammatory. International Congress and Symposium Series (ICSS) 69. London: Royal Society of Medicine Press, 1985: 209–13

    Google Scholar 

  71. McLatchie GR, Allister C, McEwan C, et al. The management of acute soft-tissue injuries in the accident and emergency department (an open comparative study of nabumetone and soluble aspirin). In: Panayi GS, Price JD, Rotman H, editors. Nabumetone: a novel anti-inflammatory. International Congress and Symposium Series (ICSS) 69. London: Royal Society of Medicine Press, 1985: 197–203

    Google Scholar 

  72. Muckle DS, Rotman H. A report on a study on the assessment of the effectiveness of nabumetone in the treatment of sports injuries by comparison with naproxen. In: Panayi GS, Price JD, Rotman H, editors. Nabumetone: a novel anti-inflammatory. International Congress and Symposium Series (ICSS) 69. London: Royal Society of Medicine Press, 1985: 187–92

    Google Scholar 

  73. Bouchier-Hayes TAI. A report on a study of the assessment of the effectiveness of nabumetone in the treatment of sports injuries by comparison with naproxen. In: Panayi GS, Price JD, Rotman H, editors. Nabumetone: a novel anti-inflammatory. International Congress and Symposium Series (ICSS) 69. London: Royal Society of Medicine Press, 1985: 203–8

    Google Scholar 

  74. Walkden L, Rotman H. A report of a study on the assessment of the effectiveness of nabumetone in the treatment of sports injuries by comparison with ibuprofen. In: Panayi GS, Price JD, Rotman H, editors. Nabumetone: a novel anti-inflammatory. International Congress and Symposium Series (ICSS) 69. London: Royal Society of Medicine Press, 1985: 193–6

    Google Scholar 

  75. Huang JQ, Sridhar S, Hunt RH. Gastrointestinal safety profile of nabumetone: a meta-analysis. Am J Med 1999; 107(6A): 55S–61S

    Article  PubMed  CAS  Google Scholar 

  76. Bernhard GC. Worldwide safety experience with nabumetone. J Rheumatol 1992; 19 Suppl. 36: 48–57

    Google Scholar 

  77. Lipani JA, Poland M. Clinical update of the relative safety of nabumetone in long-term clinical trials. Inflammopharmacology 1995; 3: 351–61

    Article  CAS  Google Scholar 

  78. Nunn B, Chamberlain PD. Effect of nabumetone (BRL 14777), a new anti-inflammatory drug, on human platelet reactivity ex vivo: comparison with naproxen. J Pharm Pharmacol 1982; 34(9): 576–9

    Article  PubMed  CAS  Google Scholar 

  79. FDA memorandum: Rofecoxib (MK-0966) [online]. Available from URL: http://www.fda.gov/ohrms/dockets/ac/01/briefing/3677b2_06_cardio.pdf [Accessed 2004 Aug 23]

  80. Willkens RF. An overview of the long-term safety experience of nabumetone. Drugs 1990; 40 Suppl. 5: 34–7

    Article  PubMed  Google Scholar 

  81. Confino-Cohen R, Goldberg A. Safe full-dose one-step nabumetone challenge in patients with nonsteroidal anti-inflammatory drug hypersensitivity. Allergy Asthma Proc 2003; 24(4): 281–4

    PubMed  CAS  Google Scholar 

  82. Fries JF, Williams CA, Bloch DA, et al. Nonsteroidal anti-inflammatory drug-associated gastropathy: incidence and risk factor models. Am J Med 1991; 91(3): 213–22

    Article  PubMed  CAS  Google Scholar 

  83. Soll AH. Pathogenesis of peptic ulcer and implications for therapy. N Engl J Med 1990; 322(13): 909–16

    Article  PubMed  CAS  Google Scholar 

  84. Hochberg MC. Association of nonsteroidal antiinflammatory drugs with upper gastrointestinal disease: epidemiologic and economic considerations. J Rheumatol 1992; 19 Suppl. 36: 63–7

    Google Scholar 

  85. Wallace JL, McKnight W, Vergnolle N. Inhibition of both cyclo-oxygenase (COX)-1 and COX-2 is required for NSAID-induced erosion formation [abstract]. Gastroenterology 2000; 118: A194

    Article  Google Scholar 

  86. Langenbach R, Morham SG, Tiano HF, et al. Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration. Cell 1995; 83(3): 483–92

    Article  PubMed  CAS  Google Scholar 

  87. Morham SG, Langenbach R, Loftin CD, et al. Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse. Cell 1995; 83(3): 473–82

    Article  PubMed  CAS  Google Scholar 

  88. Wallace JL, Reuter BK, McKnight W, et al. Selective inhibitors of cyclooxygenase-2: are they really effective, selective, and GI-safe? J Clin Gastroenterol 1998; 27 Suppl. 1: S28–34

    Article  PubMed  Google Scholar 

  89. Mizuno H, Sakamoto C, Matsuda K, et al. Induction of cyclooxygenase 2 in gastric mucosal lesions and its inhibition by the specific antagonist delays healing in mice. Gastroenterology 1997; 112(2): 387–97

    Article  PubMed  CAS  Google Scholar 

  90. Reuter BK, Asfaha S, Buret A, et al. Exacerbation of inflammation-associated colonic injury in rat through inhibition of cyclooxygenase-2. J Clin Invest 1996; 98(9): 2076–85

    Article  PubMed  CAS  Google Scholar 

  91. Gretzer B, Ehrlich K, Maricic N, et al. Selective cyclo-ox-ygenase-2 inhibitors and their influence on the protective effect of a mild irritant in the rat stomach. Br J Pharmacol 1998; 123(5): 927–35

    Article  PubMed  CAS  Google Scholar 

  92. Lichtenberger LM. Where is the evidence that cyclooxygenase inhibition is the primary cause of nonsteroidal anti-inflammatory drug (NSAID)-induced gastrointestinal injury? Topical injury revisited. Biochem Pharmacol 2001; 61(6): 631–7

    Article  PubMed  CAS  Google Scholar 

  93. Cooke AR, Goulston K. Failure of intravenous aspirin to increase gastrointestinal blood loss. BMJ 1969; 1(666): 330–2

    Article  Google Scholar 

  94. Ivey KJ, Paone DB, Krause WJ. Acute effect of systemic aspirin on gastric mucosa in man. Dig Dis Sci 1980; 25(2): 97–9

    Article  PubMed  CAS  Google Scholar 

  95. Shorrock CJ, Rees WD. Mucosal adaptation to indomethacin induced gastric damage in man: studies on morphology, blood flow, and prostaglandin E2 metabolism. Gut 1992; 33(2): 164–9

    Article  PubMed  CAS  Google Scholar 

  96. Konturek JW, Dembinski A, Konturek SJ, et al. Infection of Helicobacter pylori in gastric adaptation to continued administration of aspirin in humans. Gastroenterology 1998; 114(2): 245–55

    Article  PubMed  CAS  Google Scholar 

  97. Ligumsky M, Golanska EM, Hansen DG, et al. Aspirin can inhibit gastric mucosal cyclo-oxygenase without causing lesions in rat. Gastroenterology 1983; 84(4): 756–61

    PubMed  CAS  Google Scholar 

  98. Ligumsky M, Sestieri M, Karmeli F, et al. Rectal administration of nonsteroidal antiinflammatory drugs: effect on rat gastric ulcerogenicity and prostaglandin E2 synthesis. Gastroenterology 1990; 98 (5 Pt 1): 1245–9

    PubMed  CAS  Google Scholar 

  99. Brune K, Nurnberg B, Szelenyi I, et al. The enterohepatic circulation of some anti-inflammatory drugs may cause intestinal ulcerations. In: Rainsford KD, Velo GP, editors. Side effects of anti-inflammatory drugs. Pt 2. Boston (MA): MTP Press Limited, 1985: 29–39

    Google Scholar 

  100. Hucker HB, Zacchei AG, Cox SV, et al. Studies on the absorption, distribution and excretion of indomethasin in various species. J Pharmacol Exp Ther 1966; 153: 237–49

    CAS  Google Scholar 

  101. Yamada T, Deitch E, Specian RD, et al. Mechanisms of acute and chronic intestinal inflammation induced by indomethacin. Inflammation 1993; 17(6): 641–62

    Article  PubMed  CAS  Google Scholar 

  102. Hansen D, Aures D, Grossman MI. Comparison of intravenous and intragastric aspirin in production of antral gastric ulcers in cats. Proc Soc Exp Biol Med 1980; 164(4): 589–92

    PubMed  CAS  Google Scholar 

  103. Whittle BJ, Hansen D, Salmon JA. Gastric ulcer formation and cyclo-oxygenase inhibition in cat antrum follows parenteral administration of aspirin but not salicylate. Eur J Pharmacol 1985; 116(1–2): 153–7

    Article  PubMed  CAS  Google Scholar 

  104. Bugat R, Thompson MR, Aures D, et al. Gastric mucosal lesions produced by intravenous infusion of aspirin in cats. Gastroenterology 1976; 71(5): 754–9

    PubMed  CAS  Google Scholar 

  105. Elliott SN, Wallace JL. Nitric oxide: a regulator of mucosal defense and injury. J Gastroenterol 1998; 33(6): 792–803

    Article  PubMed  CAS  Google Scholar 

  106. Mahmud T, Rafi SS, Scott DL, et al. Nonsteroidal antiinflammatory drugs and uncoupling of mitochondrial oxidative phosphorylation. Arthritis Rheum 1996; 39(12): 1998–2003

    Article  PubMed  CAS  Google Scholar 

  107. McCormack K, Brune K. Classical absorption theory and the development of gastric mucosal damage associated with the non-steroidal anti-inflammatory drugs. Arch Toxicol 1987; 60(4): 261–9

    Article  PubMed  CAS  Google Scholar 

  108. Robert A. Prostaglandins and the gastrointestinal tract. New York: Raven Press, 1981

    Google Scholar 

  109. Hawkey CJ, Rampton DS. Prostaglandins and the gastrointestinal mucosa: are they important in its function, disease, or treatment? Gastroenterology 1985; 89(5): 1162–88

    PubMed  CAS  Google Scholar 

  110. Lanza FL. A review of gastric ulcer and gastroduodenal injury in normal volunteers receiving aspirin and other non-steroidal anti-inflammatory drugs. Scand J Gastroenterol Suppl 1989; 163: 24–31

    Article  PubMed  CAS  Google Scholar 

  111. Rainsford KD, Willis C. Relationship of gastric mucosal damage induced in pigs by antiinflammatory drugs to their effects on prostaglandin production. Dig Dis Sci 1982; 27(7): 624–35

    Article  PubMed  CAS  Google Scholar 

  112. Graham DY, Agrawal NM, Roth SH. Prevention of NSAID-induced gastric ulcer with misoprostol: multicentre, double-blind, placebo-controlled trial. Lancet 1988; II(8623): 1277–80

    Article  Google Scholar 

  113. Silverstein FE, Graham DY, Senior JR, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995; 123(4): 241–9

    PubMed  CAS  Google Scholar 

  114. Hawkey CJ, Karrasch JA, Szczepanski L, et al. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group. N Engl J Med 1998; 338(11): 727–34

    CAS  Google Scholar 

  115. Sawaoka H, Tsuji S, Tsujii M, et al. Expression of the cyclooxygenase-2 gene in gastric epithelium. J Clin Gastroenterol 1997; 25 Suppl. 1: S105–10115.

    Article  PubMed  Google Scholar 

  116. Stenson WF. Cyclooxygenase 2 and wound healing in the stomach. Gastroenterology 1997; 112(2): 645–8

    Article  PubMed  CAS  Google Scholar 

  117. Garcia Rodriguez LA, Jick H. Risk of upper gastrointestinal bleeding and performation associated with individual nonsteroidal anti-inflammatory drugs. Lancet 1994 Mar 26; 343(8900): 769–72

    Article  PubMed  CAS  Google Scholar 

  118. Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs: a meta-analysis. Ann Intern Med 1991; 115(10): 787–96

    PubMed  CAS  Google Scholar 

  119. Henry D, Dobson A, Turner C. Variability in the risk of major gastrointestinal complications from nonaspirin nonsteroidal anti-inflammatory drugs. Gastroenterology 1993; 105(4): 1078–88

    PubMed  CAS  Google Scholar 

  120. McCarthy D. Nonsteroidal anti-inflammatory drug-related gastrointestinal toxicity: definitions and epidemiology. Am J Med 1998; 105(5A): 3S–9S

    Article  PubMed  CAS  Google Scholar 

  121. Singh G, Rosen Ramey D. NSAID induced gastrointestinal complicatons: the ARMAIS perspective: 1997. J Rheumatol 1998; 25 Suppl. 51: 8–16

    Google Scholar 

  122. Florence AT, Jani PU. Novel oral drug formulations: their potential in modulating adverse effects. Drug Saf 1994; 10(3): 233–66

    Article  PubMed  CAS  Google Scholar 

  123. Tramer MR, Williams JE, Carroll D, et al. Comparing analgesic efficacy of non-steroidal anti-inflammatory drugs given by different routes in acute and chronic pain: a qualitative systematic review. Acta Anaesthesiol Scand 1998; 42(1): 71–9

    Article  PubMed  CAS  Google Scholar 

  124. Meade EA, Smith WL, DeWitt DL. Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs. J Biol Chem 1993; 268(9): 6610–4

    PubMed  CAS  Google Scholar 

  125. Rothstein R. Safety profiles of leading nonsteroidal anti-inflammatory drugs. Am J Med 1998; 105(5A): 39S–43S

    Article  PubMed  CAS  Google Scholar 

  126. Somasundaram S, Hayllar H, Rafi S, et al. The biochemical basis of non-steroidal anti-inflammatory drug-induced damage to the gastrointestinal tract: a review and a hypothesis. Scand J Gastroenterol 1995; 30(4): 289–99

    Article  PubMed  CAS  Google Scholar 

  127. Lussier A, LeBel E. Radiochromium (chromium-51) evaluation of gastrointestinal blood loss associated with placebo, aspirin, and nabumetone. Am J Med 1987; 83(4B): 15–8

    Article  PubMed  CAS  Google Scholar 

  128. Sigthorsson G, Tibbie J, Hayllar J, et al. Intestinal permeability and inflammation in patients on NSAIDs. Gut 1998; 43(4): 506–11

    Article  PubMed  CAS  Google Scholar 

  129. Appleyard M, Fireman Z, Glukhovsky A, et al. A randomized trial comparing wireless capsule endoscopy with push enteroscopy-for the detection of small-bowel lesions. Gastroenterology 2000; 119(6): 1431–8

    Article  PubMed  CAS  Google Scholar 

  130. Smale S, Tibbie J, Sigthorsson G, et al. Epidemiology and differential diagnosis of NSAID-induced injury to the mucosa of the small intestine. Best Pract Res Clin Gastroenterol 2001; 15(5): 723–38

    Article  PubMed  CAS  Google Scholar 

  131. Bjarnason I, Fehilly B, Smethurst P, et al. Importance of local versus systemic effects of non-steroidal anti-inflammatory drugs in increasing small intestinal permeability in man. Gut 1991; 32(3): 275–7

    Article  PubMed  CAS  Google Scholar 

  132. Dandona P, Jeremy JY. Nonsteroidal anti-inflammatory drug therapy and gastric side effects: does nabumetone provide a solution? Drugs 1990; 40 Suppl. 5: 16–24

    Article  PubMed  CAS  Google Scholar 

  133. Freston JW. Rationalizing cyclooxygenase (COX) inhibition for maximal efficacy and minimal adverse events. Am J Med 1999; 107 Suppl. 6A: 78S–88S

    Article  PubMed  CAS  Google Scholar 

  134. MacDonald TM, Morant SV, Robinson GC, et al. Association of upper gastrointestinal toxicity of non-steroidal anti-inflammatory drugs with continued exposure: cohort study. BMJ 1997; 315(7119): 1333–7

    Article  PubMed  CAS  Google Scholar 

  135. Singh G, Terry R, Ramey RT. Comparative toxicity of NSAIDs [abstract]. Arthritis Rheum 1997; 40(S115): 507

    Google Scholar 

  136. Singh G, Rosen Ramey D. NSAID induced gastrointestinal complications: the ARAMIS perspective–1997. Arthritis, Rheumatism, and Aging Medical Information. J Rheumatol Suppl 1998 May; 51: 8–16

    PubMed  CAS  Google Scholar 

  137. Singh B, Terry R, Ramey DR. Epidemiology of serious NSAID-related complications: a prospective multivariate lifetable analysis [abstract]. Arthritis Rheum 1997; 40: S213

    Google Scholar 

  138. Patrono C. Aspirin as an antiplatelet drug. N Engl J Med 1994; 330(18): 1287–94

    Article  PubMed  CAS  Google Scholar 

  139. Fuster V, Badimon L, Badimon JJ, et al. The pathogenesis of coronary artery disease and the acute coronary syndromes (2). N Engl J Med 1992; 326(5): 310–8

    Article  PubMed  CAS  Google Scholar 

  140. Watson DJ, Rhodes T, Guess HA. All-cause mortality and vascular events among patients with rheumatoid arthritis, osteoarthritis, or no arthritis in the UK General Practice Research Database. J Rheumatol 2003 Jun; 30(6): 1196–202

    PubMed  Google Scholar 

  141. Funk CD, Funk LB, Kennedy ME, et al. Human platelet/ erythroleukemia cell prostaglandin G/H synthase: cDNA cloning, expression, and gene chromosomal assignment. FASEB J 1991; 5(9): 2304–12

    PubMed  CAS  Google Scholar 

  142. Patrignani P, Sciulli MG, Manarini S, et al. COX-2 is not involved in thromboxane biosynthesis by activated human platelets. J Physiol Pharmacol 1999; 50(4): 661–7

    PubMed  CAS  Google Scholar 

  143. Picot D, Loll PJ, Garavito RM. The X-ray crystal structure of the membrane protein prostaglandin H2 synthase-1. Nature 1994; 367(6460): 243–9

    Article  PubMed  CAS  Google Scholar 

  144. Loll PJ, Picot D, Ekabo O, et al. Synthesis and use of iodinated nonsteroidal antiinflammatory drug analogs as crystallographic probes of the prostaglandin H2 synthase cyclooxygenase active site. Biochemistry 1996; 35(23): 7330–40

    Article  PubMed  CAS  Google Scholar 

  145. Catella-Lawson F, Reilly MP, Kapoor SC, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001; 345(25): 1809–17

    Article  PubMed  CAS  Google Scholar 

  146. FitzGerald GA. Mechanisms of platelet activation: thromboxane A2 as an amplifying signal for other agonists. Am J Cardiol 1991; 68(7): 11B-5B

    Article  Google Scholar 

  147. Di Minno G, Silver MJ, Murphy S. Monitoring the entry of new platelets into the circulation after ingestion of aspirin. Blood 1983; 61(6): 1081–5

    PubMed  Google Scholar 

  148. Patrono C, Ciabattoni G, Patrignani P, et al. Clinical pharmacology of platelet cyclooxygenase inhibition. Circulation 1985; 72(6): 1177–84

    Article  PubMed  CAS  Google Scholar 

  149. Patrignani P, Filabozzi P, Patrono C. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest 1982; 69(6): 1366–72

    Article  PubMed  CAS  Google Scholar 

  150. Weksler BB, Pett SB, Alonso D, et al. Differential inhibition by aspirin of vascular and platelet prostaglandin synthesis in atherosclerotic patients. N Engl J Med 1983; 308(14): 800–5

    Article  PubMed  CAS  Google Scholar 

  151. Burch JW, Stanford N, Majerus PW. Inhibition of platelet prostaglandin synthetase by oral aspirin. J Clin Invest 1978; 61(2): 314–9

    Article  PubMed  CAS  Google Scholar 

  152. De Caterina R, Giannessi D, Boem A, et al. Equal antiplatelet effects of aspirin 50 or 324 mg/day in patients after acute myocardial infarction. Thromb Haemost 1985; 54(2): 528–32

    PubMed  Google Scholar 

  153. FitzGerald GA, Oates JA, Hawiger J, et al. Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man. J Clin Invest 1983; 71(3): 676–88

    Article  PubMed  CAS  Google Scholar 

  154. Fitzgerald DJ, Roy L, Catella F, et al. Platelet activation in unstable coronary disease. N Engl J Med 1986; 315(16): 983–9

    Article  PubMed  CAS  Google Scholar 

  155. Vejar M, Fragasso G, Hackett D, et al. Dissociation of platelet activation and spontaneous myocardial ischemia in unstable angina. Thromb Haemost 1990; 63(2): 163–8

    PubMed  CAS  Google Scholar 

  156. SALT TSCG. Swedish Acetylsalicylic acid Low-Dose Trial (SALT) of 75mg acetylsalicylic acid as secondary prophylaxis after cerebrovascular ischaemic events. Lancet 1991; 338: 1345–9

    Article  Google Scholar 

  157. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001; 286(8): 954–9

    Article  PubMed  CAS  Google Scholar 

  158. Hawkey CJ. COX-1 and COX-2 inhibitors. Best Pract Res Clin Gastroenterol 2001; 15(5): 801–20

    Article  PubMed  CAS  Google Scholar 

  159. Hochberg MC. What have we learned from the large outcomes trials of COX-2 selective inhibitors? The rheumatologist’s perspective. Clin Exp Rheumatol 2001; 19 (6 Suppl. 25): S15–22

    PubMed  CAS  Google Scholar 

  160. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis: VIGOR Study Group. N Engl J Med 2000; 343(21): 1520–8

    Article  PubMed  CAS  Google Scholar 

  161. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000; 284(10): 1247–55

    CAS  Google Scholar 

  162. US FDA. Statistical reviewer briefing document for the advisory committee. NDA# 21-042 s-007 [online]. Available from URL: http://www.fda.gov/ohrms/dockets/ac/01/briefing/3677b2_04_stats.pdf [Accessed 2004 Jul 28]

  163. US FDA. Statistical reviewer briefing document for the advisory committee. NDA20-998 [online]. Available from URL: http://www.fda.gov/ohrms/dockets/ac/01/briefing/3677bl_04_stats.pdf [Accessed 2003 Jul 28]

  164. Scheiman JM. Outcomes studies of the gastrointestinal safety of cyclooxygenase-2 inhibitors. Cleve Clin J Med 2002; 69 Suppl. 1: SI40–6

    Article  PubMed  Google Scholar 

  165. Singh G, Goldstein J, Bensen WG, et al. SUCCESS-1 in osteoarthritis (OA) trial: celecoxib significantly reduces risk of upper GI complications compared to NSAIDs while providing similar efficacy in 13,274 randomized patients [abstract]. Ann Rheum Dis 2001; 60 Suppl. 1: 58

    Google Scholar 

  166. Goldstein JL, Correa P, Zhao WW, et al. Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis. Am J Gastroenterol 2001; 96(4): 1019–27

    Article  PubMed  CAS  Google Scholar 

  167. Cipollone F, Ganci A, Panara MR, et al. Effects of nabumetone on prostanoid biosynthesis in humans. Clin Pharmacol Ther 1995; 58(3): 335–41

    Article  PubMed  CAS  Google Scholar 

  168. Jeremy JY, Mikhailidis DP, Barradas MA, et al. The effect of nabumetone and its principal active metabolite on in vitro human gastric mucosal prostanoid synthesis and platelet function. Br J Rheumatol 1990; 29(2): 116–9

    Article  PubMed  CAS  Google Scholar 

  169. Schnitzer TJ, Donahue JR, Toomey EP, et al. Effect of nabumetone on hemostasis during arthroscopic knee surgery. Clin Ther 1998; 20(1): 110–24

    Article  PubMed  CAS  Google Scholar 

  170. Giuliano F, Ferraz JG, Pereira R, et al. Cyclooxygenase selectivity of non-steroid anti-inflammatory drugs in humans: ex vivo evaluation. Eur J Pharmacol 2001; 426(1-2): 95–103

    Article  PubMed  CAS  Google Scholar 

  171. Leese PT, Hubbard RC, Karim A, et al. Effects of celecoxib, a novel cyclooxygenase-2 inhibitor, on platelet function in healthy adults: a randomized, controlled trial. J Clin Pharmacol 2000; 40(2): 124–32

    Article  PubMed  CAS  Google Scholar 

  172. Hennan JK, Huang J, Barrett TD, et al. Effects of selective cyclooxygenase-2 inhibition on vascular responses and thrombosis in canine coronary arteries. Circulation 2001; 104(7): 820–5

    Article  PubMed  CAS  Google Scholar 

  173. Konstam MA, Weir MR, Reicin A, et al. Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib. Circulation 2001; 104(19): 2280–8

    Article  PubMed  CAS  Google Scholar 

  174. Crofford LJ. Rational use of analgesic and antiinflammatory drugs. N Engl J Med 2001; 345(25): 1844–6

    Article  PubMed  CAS  Google Scholar 

  175. Van Solingen RM, Rosenstein ED, Mihailescu G, et al. Comparison of the effects of ketoprofen on platelet function in the presence and absence of aspirin. Am J Med 2001; 111(4): 285–9

    Article  PubMed  Google Scholar 

  176. Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324(7329): 71–86

    Article  Google Scholar 

  177. Fornaro G, Rossi P, Mantica PG, et al. Indobufen in the prevention of thromboembolic complications in patients with heart disease: a randomized, placebo-controlled, double-blind study. Circulation 1993; 87(1): 162–4

    Article  PubMed  CAS  Google Scholar 

  178. Brochier ML. Evaluation of flurbiprofen for prevention of reinfarction and reocclusion after successful thrombolysis or angioplasty in acute myocardial infarction. The Flurbiprofen French Trial. Eur Heart J 1993; 14(7): 951–7

    CAS  Google Scholar 

  179. Garcia Rodriguez LA, Varas C, Patroni C. Differential effects of aspirin and non-aspirin nonsteroidal antiinflammatory drugs in the primary prevention of myocardial infarction in postmenopausal women. Epidemiology 2000; 11: 382–7

    Article  PubMed  CAS  Google Scholar 

  180. Pedersen AK, FitzGerald GA. Cyclooxygenase inhibition, platelet function, and metabolite formation during chronic sulfinpyrazone dosing. Clin Pharmacol Ther 1985; 37(1): 36–42

    Article  PubMed  CAS  Google Scholar 

  181. FitzGerald GA, Smith B, Pedersen AK, et al. Increased prostacyclin biosynthesis in patients with severe atherosclerosis and platelet activation. N Engl J Med 1984; 310(17): 1065–8

    Article  PubMed  CAS  Google Scholar 

  182. Catella-Lawson F, McAdam BF, Morrison BW, et al. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. J Pharmacol Exp Ther 1999; 289(2): 735–41

    PubMed  CAS  Google Scholar 

  183. McAdam BF, Catella-Lawson F, Mardini IA, et al. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci U S A 1999; 96(1): 272–7

    Article  PubMed  CAS  Google Scholar 

  184. Braden GA, Knapp HR, FitzGerald GA. Suppression of eicosa-noid biosynthesis during coronary angioplasty by fish oil and aspirin. Circulation 1991; 84(2): 679–85

    Article  PubMed  CAS  Google Scholar 

  185. Gimbrone Jr MA, Topper JN, Nagel T, et al. Endothelial dysfunction, hemodynamic forces, and atherogenesis. Ann N Y Acad Sci 2000; 902: 230–9

    Article  PubMed  CAS  Google Scholar 

  186. James MJ, Walsh JA, Foreman RK. Effect of 50mg entericcoated aspirin (Astrix) on thromboxane and prostacyclin synthesis. Aust N Z J Surg 1987; 57(10): 763–6

    Article  PubMed  CAS  Google Scholar 

  187. Olsen NV, Jensen NG, Hansen JM, et al. Non-steroidal anti-inflammatory drugs and renal response to exercise: a comparison of indomethacin and nabumetone. Clin Sci (Lond) 1999; 97(4): 457–65

    Article  CAS  Google Scholar 

  188. Whelton A. Renal and related cardiovascular effects of conventional and COX-2-specific NSAIDs and non-NSAID analgesics. Am J Ther 2000; 7(2): 63–74

    Article  PubMed  CAS  Google Scholar 

  189. Thakur V, Cook ME, Wallin JD. Antihypertensive effect of the combination of fosinopril and HCTZ is resistant to interference by nonsteroidal antiinflammatory drugs. Am J Hypertens 1999; 12 (9 Pt 1): 925–8

    Article  PubMed  CAS  Google Scholar 

  190. Palmer R, Weiss R, Zusman RM, et al. Effects of nabumetone, celecoxib, and ibuprofen on blood pressure control in hypertensive patients on angiotensin converting enzyme inhibitors. Am J Hypertens 2003; 16(2): 135–9

    Article  PubMed  CAS  Google Scholar 

  191. Day RO, Henry DA, Muirden KD, et al. Non-steroidal anti-inflammatory drug induced upper gastrointestinal haemorrhage and bleeding. Med J Aust 1992; 157(11–12): 810–2

    PubMed  CAS  Google Scholar 

  192. Adverse Drug Reactions Advisory Committee (ADRAC). Celecoxib: early Australian reporting experience. Aust Adv Drug React Bull 2000; 19: 6–7

    Google Scholar 

  193. Committee on Safety of Medicines. In focus: rofecoxib [abstract]. Curr Probl Pharmacovigil 2000; 26: 13

    Google Scholar 

  194. Crofford LJ, Oates JC, McCune WJ, et al. Thrombosis in patients with connective tissue diseases treated with specific cyclooxygenase 2 inhibitors: a report of four cases. Arthritis Rheum 2000; 43(8): 1891–6

    Article  PubMed  CAS  Google Scholar 

  195. Dunn M. The role of arachidonic acid metabolites in renal homeostasis: non-steroidal anti-inflammatory drugs renal function and biochemical, histological and clinical effects and drug interactions. Drugs 1987; 33 Suppl. 1: 56–66

    Article  PubMed  CAS  Google Scholar 

  196. Crofford LJ. COX-1 and COX-2 tissue expression: implications and predictions. J Rheumatol 1997; 24 Suppl. 49: 15–9

    Google Scholar 

  197. Palmer BF, Henrich WL. Clinical acute renal failure with nonsteroidal anti-inflammatory drugs. Semin Nephrol 1995; 15(3): 214–27

    PubMed  CAS  Google Scholar 

  198. Lipsky PE. Specific COX-2 inhibitors in arthritis, oncology, and beyond: where is the science headed? J Rheumatol 1999; 26 Suppl. 56: 25–30

    Google Scholar 

  199. Breyer MD. COX2 selective NSAIDs and renal function: gain without pain? Kidney Int 1999; 55(2): 738–9

    Article  PubMed  CAS  Google Scholar 

  200. KomhoffM, Grone HJ, Klein T, et al. Localization of cyclooxy-genase-1 and -2 in adult and fetal human kidney: implication for renal function. Am J Physiol 1997; 272 (4 Pt 2): F460–8

    Google Scholar 

  201. Komers R, Anderson S, Epstein M. Renal and cardiovascular effects of selective cyclooxygenase-2 inhibitors. Am J Kidney Dis 2001; 38(6): 1145–57

    Article  PubMed  CAS  Google Scholar 

  202. Khan KN, Paulson SK, Verburg KM, et al. Pharmacology of cyclooxygenase-2 inhibition in the kidney. Kidney Int 2002; 61(4): 1210–9

    Article  PubMed  CAS  Google Scholar 

  203. Stichtenoth DO, Frolich JC. COX-2 and the kidneys. Curr Pharm Des 2000; 6(17): 1737–53

    Article  PubMed  CAS  Google Scholar 

  204. Brater DC, Harris C, Redfern JS, et al. Renal effects of COX-2-selective inhibitors. Am J Nephrol 2001; 21(1): 1–15

    Article  PubMed  CAS  Google Scholar 

  205. Guan Y, Chang M, Cho W, et al. Cloning, expression, and regulation of rabbit cyclooxygenase-2 in renal medullary interstitial cells. Am J Physiol 1997; 273 (1 Pt 2): F18–26

    PubMed  CAS  Google Scholar 

  206. Harris RC, McKanna JA, Akai Y, et al. Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction. J Clin Invest 1994; 94(6): 2504–10

    Article  PubMed  CAS  Google Scholar 

  207. Pugliese F, Cinotti GA. Nonsteroidal anti-inflammatory drugs (NSAIDs) and the kidney. Nephrol Dial Transplant 1997; 12(3): 386–8

    Article  PubMed  CAS  Google Scholar 

  208. Murray MD, Brater DC. Effects of NSAIDs on the kidney. Prog Drug Res 1997; 49: 155–71

    PubMed  CAS  Google Scholar 

  209. Schlondorff D. Renal complications of nonsteroidal anti-inflammatory drugs. Kidney Int 1993; 44(3): 643–53

    Article  PubMed  CAS  Google Scholar 

  210. Bennett WM, Henrich WL, Stoff JS. The renal effects of nonsteroidal anti-inflammatory drugs: summary and recommendations. Am J Kidney Dis 1996; 28 (1 Suppl. 1): S56–62

    Article  PubMed  CAS  Google Scholar 

  211. Freed MI, Audet PR, Zariffa N, et al. Comparative effects of nabumetone, sulindac, and indomethacin on urinary prostaglandin excretion and platelet function in volunteers. J Clin Pharmacol 1994; 34(11): 1098–108

    PubMed  CAS  Google Scholar 

  212. Cook ME, Wallin JD, Thakur VD, et al. Comparative effects of nabumetone, sulindac, and ibuprofen on renal function. J Rheumatol 1997; 24(6): 1137–44

    PubMed  CAS  Google Scholar 

  213. Cangiano JL, Figueroa J, Palmer R. Renal hemodynamic effects of nabumetone, sulindac, and placebo in patients with osteoarthritis. Clin Ther 1999; 21(3): 503–12

    Article  PubMed  CAS  Google Scholar 

  214. Perazella MA, Tray K. Selective cyclooxygenase-2 inhibitors: a pattern of nephrotoxicity similar to traditional nonsteroidal anti-inflammatory drugs. Am J Med 2001; 111(1): 64–7

    Article  PubMed  CAS  Google Scholar 

  215. Rocha JL, Fernandez-Alonso J. Acute tubulointerstitial nephritis associated with the selective COX-2 enzyme inhibitor, rofecoxib. Lancet 2001; 357(9272): 1946–7

    Article  PubMed  CAS  Google Scholar 

  216. Henao J, Hisamuddin I, Nzerue CM, et al. Celecoxib-induced acute interstitial nephritis. Am J Kidney Dis 2002; 39(6): 1313–7

    Article  PubMed  Google Scholar 

  217. Eversmeyer W, Poland M, DeLapp RE, et al. Safety experience with nabumetone versus diclofenac, naproxen, ibuprofen, and piroxicam in osteoarthritis and rheumatoid arthritis. Am J Med 1993; 95(2A): 10S–8S

    Article  PubMed  CAS  Google Scholar 

  218. Morgan GJ, Poland M, De Lapp RE. Efficacy and safety of nabumetone versus diclofenac, naproxen, ibuprofen and piroxicam in the elderly. Am J Med 1993 Aug 9; 95 Suppl. 2A: 19S–27S

    Article  PubMed  CAS  Google Scholar 

  219. DeWitt DL, Meade EA, Smith WL. PGH synthethase isoenzyme selectivity: the potential for safer nonsteroidal antiinflammatory drugs. Am J Med 1993; 95(2A): 40S–4S

    Article  Google Scholar 

  220. Dinchuk JE, Car BD, Focht RJ, et al. Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II. Nature 1995; 378(6555): 406–9

    Article  PubMed  CAS  Google Scholar 

  221. Eckmann L, Stenson WF, Savidge TC, et al. Role of intestinal epithelial cells in the host secretory response to infection by invasive bacteria: bacterial entry induces epithelial prostaglandin synthase-2 expression and prostaglandin E2 and F2alpha production. J Clin Invest 1997; 100(2): 296–309

    Article  PubMed  CAS  Google Scholar 

  222. Amin AR, Attur M, Patel RN, et al. Superinduction of cyclooxygenase-2 activity in human osteoarthritis-affected cartilage: influence of nitric oxide. J Clin Invest 1997; 99(6): 1231–7

    Article  PubMed  CAS  Google Scholar 

  223. Stichtenoth DO, Wagner B, Frolich JC. Effect of selective inhibition of the inducible cyclooxygenase on renin release in healthy volunteers. J Investig Med 1998; 46(6): 290–6

    PubMed  CAS  Google Scholar 

  224. Brooks DP, Adams J, DePalma PD, et al. The selective cyclooxygenase-2 (COX-2) inhibitor, celecoxib, but not 6-MNA affects renal hemodynamic and renal function in the dog [abstract]. J Invest Med 1998 Mar; 46 (3 Suppl. S): 227A

    Google Scholar 

  225. Sirois J, Dore M. The late induction of prostaglandin G/H synthase-2 in equine preovulatory follicles supports its role as a determinant of the ovulatory process. Endocrinology 1997; 138(10): 4427–34

    Article  PubMed  CAS  Google Scholar 

  226. Rossat J, Maillard M, Nussberger J. Acute renal effects of selective inhibition of cyclooxygenase-2 in healthy salt-depleted subjects [abstract no.]. J Am Soc Nephrol 1998; 9: 346A

    Google Scholar 

  227. Pairet M, Churchill L, Engelhardt G. Differential inhibition of cyclooxygenases 1 and 2 by NSAIDs. Dordrecht: Kluwer Academic Publishers, 1996

    Google Scholar 

  228. Jouzeau JY, Terlain B, Abid A, et al. Cyclo-oxygenase isoenzymes: how recent findings affect thinking about nonsteroidal anti-inflammatory drugs. Drugs 1997; 53(4): 563–82

    Article  PubMed  CAS  Google Scholar 

  229. Truitt KE, Sperling RS, Ettinger Jr WH, et al. A multicenter, randomized, controlled trial to evaluate the safety profile, tolerability, and efficacy of rofecoxib in advanced elderly patients with osteoarthritis. Aging (Milano) 2001; 13(2): 112–21

    CAS  Google Scholar 

  230. Stricker S. Aus der Traubschen Klinik. Ueber die Resultate der Behandlung der Polyarthritis Rheumatica mit Salicylsäure. Berliner Klinische Wochestchr 1876; 13: 1–2, 8, 13, 15

    Google Scholar 

Download references

Acknowledgements

The authors have no conflicts of interest directly relevant to the content of this review and have not received any funding for the preparation of this manuscript. However, the authors were assisted by Meda AB, Sweden, the company developing the drug, in locating supplemental bibliographical information.

Author information

Authors and Affiliations

  1. Department of Clinical Pharmacology, Sahlgrenska University Hospital, SE 413 45, Göteborg, Sweden

    Thomas Hedner

  2. Department of Nephrology, Sahlgrenska University Hospital, Göteborg, Sweden

    Ola Samulesson

  3. Department of Cardiology, Sahlgrenska University Hospital, Göteborg, Sweden

    Peter Währborg

  4. Department of Hematology, Sahlgrenska University Hospital, Göteborg, Sweden

    Hans Wadenvik

  5. Department of Gastroenterology, Kärnsjukhuset, Skövde, Sweden

    Kjell-Arne Ung

  6. Department of Medical Epidemiology, Karolinska Institute, Stockholm, Sweden

    Anders Ekbom

Authors
  1. Thomas Hedner
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ola Samulesson
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Peter Währborg
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hans Wadenvik
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kjell-Arne Ung
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Anders Ekbom
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Thomas Hedner.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hedner, T., Samulesson, O., Währborg, P. et al. Nabumetone. Drugs 64, 2315–2343 (2004). https://doi.org/10.2165/00003495-200464200-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200464200-00004

Keywords

Search

Navigation